Cadrenal Therapeutics, Inc. · NASDAQ:CVKD
Cadrenal Therapeutics — Investor Presentation (September 2024)
34 slides from Cadrenal Therapeutics's investor presentation, September 2024
Slide 1: Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. NASDAQ: CVKD September 2024
Slide 2: Caution Concerning Forward-looking Statements
Caution Concerning Forward-looking Statements This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about futu
Slide 3: Cadrenal Therapeutics Overview
Cadrenal Therapeutics Overview Late-stage Biopharma Developing a New Anticoagulant to Improve Care for Underserved Warfarin-dependent Patients Our Phase 3-ready drug candidate, tecarfarin, is a new vitamin K antagonist (VKA) anticoagulant expected to provide superior and safer anticoagulation than w
Slide 4: Three Top Potential Indications of Tecarfarin
Three Top Potential Indications of Tecarfarin Two Orphan Drug and One Fast Track Designations Focused on patients with implanted cardiac devices or • [We are committed to developing rare cardiovascular conditions that require chronic anticoagulation novel therapeutics…thru innovation, collaboration,
Slide 5: Key Investment Highlights for Cadrenal Opportunity
Key Investment Highlights for Cadrenal Opportunity Large Market of NO ANTICOAGULATION DRUGS INDICATED FOR THOSE WITH 1 Underserved IMPLANTED CV DEVICES OR RARE CV CONDITIONS requiring Patients chronic anticoagulation Data Shows Safety and Efficacy Extensive safety data from 11 clinical trials demons
Slide 6: Gaps in Modern Heart Failure and Chronic Kidney Disease Research
Gaps in Modern Heart Failure and Chronic Kidney Disease Research Interdependence of the Heart and Kidney in Chronic Kidney Disease (CKD) and Heart Failure (HF) 49% of HF patients also have CKD, and an estimated 17–21% of CKD patients develop de novo HF1 6 1Damman K, Valente MAE, Voors AA, et al. Ren
Slide 7: Tecarfarin Clinical Development Pipeline
Tecarfarin Clinical Development Pipeline Potential 2024 catalysts for future milestones to build enterprise value Development Phase Discovery Preclinical Phase I Phase II Phase III Program Prioritized Target Indications Regulatory Strategy/Status FDA Orphan Drug Designation Granted Left Ventricular
Slide 8: A Review of Tecarfarin
A Review of Tecarfarin Tecarfarin is the ONLY anticoagulant in development for patients with LVADs or rare cardiovascular conditions HOW TECARFARIN COMPARES Tecarfarin is metabolized via a different pathway than warfarin, thus its efficacy is not affected by drug-drug interactions or kidney impairme
Slide 9: The Problem: Patients with Implanted Cardiac Devices and Rare CV Conditions Lack Effective Anticoagulation
The Problem: Patients with Implanted Cardiac Devices and Rare CV Conditions Lack Effective Anticoagulation Both Warfarin and DOACs are not FDA-approved for patients with LVADs or many rare CV conditions SIGNIFICANT ISSUES WITH ONLY CHOICES FOR THESE PATIENTS Warfarin DOACs (Pradaxa, Xarelto, Eliquis
Slide 10: ARIES-HM3 Study Documents Impact of Poor Anticoagulation Quality in LVAD Patients
ARIES-HM3 Study (Sponsored by Abbott) Documents the Impact of Poor Anticoagulation Quality of Adverse Events in LVAD patients • Rate of severe bleeding Median TTR significantly increased when 0.6 60 Event per patients per year TTR falls below 56% • Mean TTR in LVAD patients 0.4 40 treated with warfa
Slide 11: Bleeding Rate in LVAD Patients is a Major Problem
Bleeding Rate in LVAD Patients is a Major Problem Poor quality anticoagulation, manifest as sub-target TTR, is the cause Recent clinical evidence from the ARIES-HM3 (Abbott) study documents the consequences of suboptimal anticoagulation with warfarin in LVAD patients • Time in Therapeutic Range (TTR
Slide 12: Phase 2/3 Trial Shows Tecarfarin Improved TTR, Fewer Thrombotic and Hemorrhagic Events
Phase 2/3 Trial Shows Tecarfarin results in improved TTR, with Fewer Thrombotic and Hemorrhagic Events 71 Time in Therapeutic Range (TTR) using Observed Values 70 Tecafarin Tecarfarin had fewer Warfarin Warfarin Tecarfarin thrombotic events 69 p=0.04 compared to warfarin 2 2 68 Randomized, double- 6
Slide 13: Tecarfarin PK Trial in Severe CKD Patients
Tecarfarin Phase 1 PK Trial in Stage 4 CKD Patients Provides Evidence that CKD Does Not Alter Tecarfarin Exposure While Warfarin Exposure is Increased Tecarfarin metabolism not as impacted by kidney failure Percent Increase in Exposure for Chronic Kidney Disease Subjects vs Healthy subjects for Warf
Slide 14: The Solution: Tecarfarin Aims to Solve Warfarin's Major Problems
The Solution: Tecarfarin Aims to Solve Warfarin’s Major Problems and Be the Superior, Safer Choice X ✓ SOLUTION: Tecarfarin Warfarin: High risk for bleeding solves warfarin challenges and other major events DECREASING MAJOR EVENTS SUCH AS Significant variability with frequent STROKE & BLEEDING dosin
Slide 15: LVADs are a Double-digit Growth Market
LVADs are a Double-digit Growth Market LVAD Market by Application and Geography – Forecast and Analysis 2021-2025 Market growth will ACCELERATE at a CAGR of 12.23 % 46% of the growth will originate from North America Source: LVADS Market Size, Share, Growth, Trends Industry Analysis Forecast 2025 Te
Slide 16: Proposed Tecarfarin Pivotal Trial Design for LVAD Patients
Proposed Tecarfarin Pivotal Trial Design for LVAD Patients Tecarfarin Anticoagulation and Hemocompatibility in LVAD Patients A randomized, blinded, phase 3, multicenter study to evaluate the efficacy and safety of tecarfarin compared to warfarin in patients with an approved left-ventricular assist d
Slide 17: Attractive Addressable Market Opportunities
Attractive Addressable Market Opportunities US market potential estimated @ $2 billion+ for three targeted implanted CV device and rare CV conditions Left Ventricular Assist Devices End-stage Approximately Kidney Disease with AFib >$2 Billion Combined Peak Annual Market Potential* Mechanical Heart V
Slide 18: Financial Summary
Financial Summary Cap Table (reflects August ‘24 reverse split) 2024 Financial Results – 6 Months ended June 30th Cash (as of 6/30/2024) $5.0 million Operating Expenses (excluding non-cash items) $3.7 million Debt NONE Cash used in operating activities $3.4 million Common Shares Outstanding 1,182,22
Slide 19: Leadership Team: Clinical to Commercial Expertise
Leadership Team: Clinical to Commercial Expertise Quang Pham Douglas Losordo, MD Matthew Szot, CPA Jeff Cole CEO & Founder, Chairman Chief Medical Officer Chief Financial Officer Chief Operating Officer John R. Murphy Steven Zelenkofske, DO Glynn Wilson, PhD Robert Lisicki Board Member Board Member
Slide 20: Scientific Advisors with Deep Experience in CV and Beyond
Scientific Advisors with Deep Experience in CV and Beyond Mandeep, Mehra MD, MSc, Richard Whitlock, MD Michael Lincoff, MD Elaine M. Hylek, MD, MPH FRCP Cardiac Surgeon and Professor of Surgery, Vice Chairman, Dept. of Cardiovascular Medicine, Professor of Medicine, McMaster Cleveland Clinic Boston
Slide 21: Why Cadrenal Now?
Why Cadrenal Now? CLEAR FROM RECENT DATA that tecarfarin has attractive, defined opportunity in patients where warfarin CHALLENGES ARE HUGE BURDEN and DOACs, with little or negative relevant data, are not the solution Phase 3-ready Data Shows Bus Dev Progress Orphan Attractive Market Candidate Super
Slide 22: Contact Us
Contact Us Quang Pham CEO & Founder [email protected] Matthew Szot CFO [email protected] 22
Slide 23: APPENDIX
APPENDIX CADRENAL
Slide 24: Bleeding Rate by TTR Increments
Bleeding Rate by TTR Increments Incremental improvement of 10% above the median of 56% trends in a significant reduction in bleeding rate Placebo Aspirin Median TTR Median (Q1, Q3) Median (Q1, Q3) P-value 60 INR Distribution 2.3 (2.1, 2.4) 2.3 (2.0, 2.5) 0.8227 Event per patients per year Eligible F
Slide 25: The Impact of TTR on Bleeding in ARIES-HM3
The Impact of TTR on Bleeding in ARIES-HM3 Bleeding Components Bleeding of the Secondary End Point 60 p-value <0.0001 50% TTR < 56% Event per 100 patient year 49.15 TTR ≥ 56% 40% Rate of Bleeding 30.3 40 30% 22.1 21.4 26.43 20% 20 10.3 10% HR: 1.381 (0.978,1.951); p=0.004 0% 0 3 6 9 12 0 Months Afte
Slide 26: Strategies to Mitigate Bleeding Complications with HM3 LVAD
Strategies to Mitigate Bleeding Complications with HM3 LVAD A Bleeding Paradox? Cikes M, Yuzefpolskaya M, Gustafsson F, Mehra MR. J Card Fail. 2024; S1071-9164(24)00318-X. 26
Slide 27: Tecarfarin's Metabolic Advantage
Tecarfarin’s Metabolic Advantage Tecarfarin is metabolized via an alternate pathway that is abundant and essentially insaturable, thereby avoiding the bottleneck in the CYP450 pathway where warfarin in metabolized. Warfarin Tecarfarin CYP450 Human Carboxylesterase 2 (CES2) Drug interactions R-Warfar
Slide 28: Warfarin Metabolism via CYP450 is Complicated by Competitors, Inhibitors and Inducers
Warfarin Metabolism via CYP450 is Complicated by Known Competitors, Inhibitors and Inducers and the Established Impact of Genetic Variants Enzymes Substrates Inhibitors Inducers amlodipine, simvastatin, ciprofloxacin, simvastatin, efavirenz, warfarin, amiodarone, ketoconazole, ritonavir, pentobarbit
Slide 29: Tecarfarin is Metabolized via the Human Carboxyl Esterase Pathway (CES2)
Tecarfarin is Metabolized via the Human Carboxyl Esterase 2 Pathway (CES2) Provides More Effective, Safe, and More Consistent Anti-coagulation Enzymes Substrates Inhibitors Inducers CES2 Substrate Drugs amlodipine, simvastatin, ciprofloxacin, simvastatin, efavirenz, Antiplatelet/Anticoagulants CNS a
Slide 30: Vitamin K Antagonism Inhibits Multiple Factors vs. Single Targets of Newer Agents
Vitamin K Antagonism Inhibits Multiple Factors (II, VII, IX, X, Proteins C & S) in the Clotting Cascade vs. Single Targets of Newer Agents Proven mechanism of action resulting in clinically meaningful anticoagulation in certain conditions where DOACs have failed SINGLE-TARGET CONTACT ACTIVATION DOAC
Slide 31: Tecarfarin Phase 3 Trial Design for ESKD and AFib
Tecarfarin Phase 3 Trial Design for ESKD and AFib Tecarfarin vs. Placebo in Patients with ESKD and AFib Randomized, Double-Blind, Placebo-Controlled Planned Enrollment N = 492 12-month follow-up Tecarfarin (n = 246) for Primary Endpoint of time to ESKD (eGFR < 15 mL/min/1.73 mm2) R combined endpoint
Slide 32: Significant Underserved Patient Populations
Significant Underserved Patient Populations Despite the significantly increased risk of stroke in ESKD patients with AFib, most patients are not anticoagulated due to the lack of evidence of benefit Use of warfarin in ESKD + AFib Patients1 (N=9,974)1 (N=47,480)2 100% 80% Most patients 78.0% with ESK
Slide 33: TTR Decreases with CKD Severity for AFib Patients on Warfarin
TTR Decreases with CKD Severity for AFib Patients on Warfarin AFib Patients with ESKD on Warfarin are Poorly Controlled with TTR of 42-51%, compared to the TTR goal of 70% or greater TTR of AFib patients with CKD on Warfarin by eGFR Group Time in Therapeutic Range (TTR)1,2,5 ESKD Patients o Well-e
Slide 34: Dabigatran Versus Warfarin in Patients with Mechanical Heart Valves
Dabigatran Versus Warfarin in Patients with Mechanical Heart Valves EXCESS RISK AND NO BENEFIT First Freedom Thromboembolic from EventEvent First Thromboembolic 1.0 Warfarin Probability of Event Free Survival 0.9 0.8 Trial terminated prematurely 0.7 due to an excess of thromboembolic and bleeding 0.
Cadrenal Therapeutics — Investor Presentation (September 2024) on 6ix